ASCO GU 2021: Analysis of CheckMate 214 Reveals Patterns of Progression That Could Help Direct Future Therapy
New lesion only progression was most common with nivolumab-ipilimumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.